Aardvark Therapeutics' stock dropped 32% following the FDA's clinical hold on its Prader-Willi Syndrome drug, ARD-101, after serious safety concerns led to a voluntary trial pause. This follows an earlier 56% drop when the company stopped its Phase 3 trial due to safety risks. The situation has triggered an investigation into whether Aardvark misled investors about the drug's safety and FDA communications. Investors with losses are encouraged to participate in the ongoing legal inquiry.
Wedbush increased its price target for Scholar Rock to $64 from $58 and kept an "Outperform" rating ahead of the FDA's September 30 decision on Scholar Rock's investigational SMA drug, apitegromab. This drug could be the first muscle-targeted therapy...
IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, will conduct a 1-for-30 reverse stock split on August 27, 2026. This move aims to increase its share price, currently at $0.11, to meet the Nasdaq Capital Market's minimum...
Buckle, Inc. reported strong Q2 earnings with an EPS of $0.87, surpassing analyst estimates of $0.81, and revenue of $319.82 million, slightly above expectations. The company saw a 4.6% increase in net sales, driven by growth in both comparable-store...
KE Holdings Inc. reported Q2 2026 earnings with an EPS of $0.42, surpassing the $0.31 consensus estimate. Although revenue declined 5.7% year-over-year to about $3.60 billion, the company doubled its net income thanks to effective cost controls and o...
Tesla delivered a record 480,126 vehicles but saw its operating margin drop to 1.4% amid heavy investment in R&D and new projects like Optimus and AI compute. Meanwhile, SpaceX, after its $85.7 billion IPO, grew revenue by 92% year-over-year, driven ...
